Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection

Sponsor
AGUNCO Obstetrics and Gynecology Centre (Other)
Overall Status
Completed
CT.gov ID
NCT01571141
Collaborator
(none)
1
2

Study Details

Study Description

Brief Summary

Human papillomavirus (HPV) infection is a worldwide problem strictly linked to the development of cervical cancer. Persistence of the infection is one of the main factors responsible for the invasive progression and women diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection.

In this study the investigators will evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based local treatment in improve the viral clearance reducing the time exposure to the infection and avoiding the complications associated with the invasive treatments currently available.

Women diagnosed with HPV infection were randomly assigned to receive six months of treatment with a PHMB-based gynaecological solution (Monogin®) or to remain untreated for the same period of time.

The administration of Monogin® has been performed every three days for fifteen days and then every fifteen days for the subsequent six months.

Condition or Disease Intervention/Treatment Phase
  • Device: Monogin
Phase 4

Study Design

Study Type:
Interventional

Arms and Interventions

Arm Intervention/Treatment
Experimental: Monogin

Device: Monogin
Gynaecological solution with polyhexamethylene biguanide, pH 4.0

No Intervention: No intervention

Outcome Measures

Primary Outcome Measures

  1. Number of patients with no HPV infection []

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • pathologic Pap smear

  • positive "high risk" HPV DNA test

  • positive colposcopy examination

Exclusion Criteria:
  • patients who had undergone wart therapy in the previous six months

  • pregnancy

  • invasive disease

  • immunosuppression

  • previous HPV vaccination

Contacts and Locations

Locations

Site City State Country Postal Code
1 Consultorio Familiare Terme Vigliatore, A.S.P. 5 Messina Italy

Sponsors and Collaborators

  • AGUNCO Obstetrics and Gynecology Centre

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
AGUNCO Obstetrics and Gynecology Centre
ClinicalTrials.gov Identifier:
NCT01571141
Other Study ID Numbers:
  • PHMB_HPV
First Posted:
Apr 5, 2012
Last Update Posted:
Apr 19, 2012
Last Verified:
Jun 1, 2011
Keywords provided by AGUNCO Obstetrics and Gynecology Centre
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2012